Shaili Gupta

Summary

Publications

  1. pmc Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications
    Shaili Gupta
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    J Urban Health 86:263-79. 2009
  2. doi request reprint Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants
    Shaili Gupta
    Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA
    J Int Assoc Physicians AIDS Care (Chic) 8:87-92. 2009
  3. doi request reprint Persistent and relapsing babesiosis in immunocompromised patients
    Peter J Krause
    Division of Infectious Diseases, Connecticut Children s Medical Center, and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut 06106, USA
    Clin Infect Dis 46:370-6. 2008

Collaborators

  • Frederick L Altice
  • Max Lataillade
  • Gail Skowron
  • M J Kozal
  • Peter J Krause
  • Donald Heiman
  • Barry Hartman
  • Jeffrey A Gelfand
  • Edward L Pesanti
  • Edouard Vannier
  • Andrew Spielman
  • Francisco M Marty
  • Mary Young
  • Gary P Wormser
  • Benjamin E Gewurz
  • Kenneth Dardick
  • Richard R Furman
  • Ellen Neuhaus
  • David Hill
  • Gunther Hsue
  • Morton Coleman
  • Ivo M Foppa
  • Jennifer E Girotto
  • Diane Christianson
  • John Dickason
  • Carlo McCalla
  • Sam R Telford
  • Frank J Bia

Detail Information

Publications3

  1. pmc Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications
    Shaili Gupta
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    J Urban Health 86:263-79. 2009
    ..We present a review of diagnosis, prevention, and the recently streamlined treatment guidelines for management of HBV infection in correctional settings, and discuss the implications and public health impact of these measures...
  2. doi request reprint Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants
    Shaili Gupta
    Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA
    J Int Assoc Physicians AIDS Care (Chic) 8:87-92. 2009
    ..All patients tolerated this regimen over a course of 25 to 82 weeks, and had good virologic and immunologic outcome with a decrease in HIV RNA levels to <50 copies/mL and a mean CD4 count increase of 234 cells/mm(3)...
  3. doi request reprint Persistent and relapsing babesiosis in immunocompromised patients
    Peter J Krause
    Division of Infectious Diseases, Connecticut Children s Medical Center, and Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut 06106, USA
    Clin Infect Dis 46:370-6. 2008
    ..Although patients experiencing babesiosis that is unresponsive to standard antimicrobial therapy have been described, the pathogenesis, clinical course, and optimal treatment regimen of such cases remain uncertain...